Press Releases

Date Title and Summary
Toggle Summary Kezar Life Sciences to Present at Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif. , Nov. 14, 2019 (GLOBE NEWSWIRE) -- Kezar Life Sciences , Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today announced members of the executive
Toggle Summary Kezar Announces Promising New Data with KZR-616 at the American College of Rheumatology Annual Meeting
Step-up dose titration lowered GI side effects while maintaining clinical activity Majority of patients completing 13 weeks of treatment demonstrated significant improvement on at least 2 measures of disease activity Conference Call and Webcast today at 8:30am EST MISSION Phase 1b Study Design
Toggle Summary Kezar Life Sciences to Host Conference Call and Webcast during the American College of Rheumatology Annual Meeting to Discuss Updated Results with KZR-616
Conference call and webcast scheduled for Tuesday, November 12th at 8:30am EST SOUTH SAN FRANCISCO, Calif. , Nov. 08, 2019 (GLOBE NEWSWIRE) -- Kezar Life Sciences , Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet
Toggle Summary Kezar Life Sciences Reports Third Quarter 2019 Financial Results and Provides Business Update
Additional data from the ongoing Phase 1b portion of the MISSION study to be presented at the 2019 ACR/ARP Meeting in Atlanta, GA Phase 2 MISSION, PRESIDIO, and MARINA trials with KZR-616 are progressing KZR-261 nominated as the first oncology clinical candidate from the Protein Secretion Program
Toggle Summary Kezar Life Sciences Announces Presentations of Four Abstracts at the 2019 ACR/ARP Annual Meeting
SOUTH SAN FRANCISCO, Calif. , Oct. 01, 2019 (GLOBE NEWSWIRE) -- Kezar Life Sciences , Inc. (Nasdaq:  KZR ), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today announced four poster presentations
Toggle Summary Kezar Life Sciences to Present at the 2019 Cantor Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif. , Sept. 27, 2019 (GLOBE NEWSWIRE) -- Kezar Life Sciences , Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today announced that John Fowler , Chief
Toggle Summary Kezar Life Sciences Announces Presentations at Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today announced that members of the senior
Toggle Summary Kezar Life Sciences Announces Presentations at Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif. , Aug. 28, 2019 (GLOBE NEWSWIRE) -- Kezar Life Sciences , Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today announced that members of the senior
Toggle Summary Kezar Life Sciences Reports Second Quarter 2019 Financial Results and Provides Business Update
Promising data reported from the Phase 1b portion of MISSION, a first-in-patient study of KZR-616; Phase 2 portion of MISSION in LN patients has been initiated Phase 2 PRESIDIO and MARINA trials have been initiated evaluating KZR-616 in DM, PM, AIHA, and ITP patients Nomination of first oncology
Toggle Summary Kezar Life Sciences Announces Promising Data from First in Patient Study of KZR-616 at EULAR 2019 Annual Meeting
Repeat dosing of KZR-616 demonstrates tolerability and broad and consistent evidence of efficacy across multiple measures of disease activity Patients receiving KZR-616 have not experienced the hematologic and constitutional toxicities seen with approved nonselective proteasome inhibitors Phase 2